Assignee
CENTESSA PHARMACEUTICALS UK LTD
GB·8 granted patents·12 pending applications·0 citations·filing 2019–2025
Top patents by PatentIndex Score
20 records- 0184US2025109202A1Anti-CD47 BINDING AGENTSCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 0283US2026042850A1Anti c-met antibodiesCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
- 0378US12415861B2Anti C-MET antibodiesCENTESSA PHARMACEUTICALS UK LTD·Filed 2023·Granted Sep 16, 2025·0 cites·19 claims
- 0474US2025236629A1Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 0574US2024294655A1Antigen binding molecules that bind lightCENTESSA PHARMACEUTICALS UK LTD·Filed 2023·Application pending·0 cites
- 0669US12227580B2Antigen binding molecules that bind LIGHTCENTESSA PHARMACEUTICALS UK LTD·Filed 2022·Granted Feb 18, 2025·0 cites·24 claims
- 0769US12221422B2Compounds and their use for the treatment of alpha1-antitrypsin deficiencyCENTESSA PHARMACEUTICALS UK LTD·Filed 2022·Granted Feb 11, 2025·0 cites·10 claims
- 0869US2025109206A1Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereofCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 0968US2025002585A1Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereofCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 1067US2025100968A1Bicyclic-heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 1166US2026015420A1Cd47 binding agentsCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
- 1264US12291507B2Compounds and their use for the treatment of ALPHA1-antitrypsin deficiencyCENTESSA PHARMACEUTICALS UK LTD·Filed 2022·Granted May 6, 2025·0 cites·20 claims
- 1364US12286402B2Compounds and their use for the treatment of alpha1-antitrypsin deficiencyCENTESSA PHARMACEUTICALS UK LTD·Filed 2022·Granted Apr 29, 2025·0 cites·19 claims
- 1463US2025289828A1Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
- 1562US2024197707A1Compositions and their Use for the Treatment of A1-Antitrypsin DeficiencyCENTESSA PHARMACEUTICALS UK LTD·Filed 2023·Application pending·0 cites
- 1661US2024360175A1Peptide derivatives and related uses as orexin agonistsCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 1760US12365672B2Compounds and their use for the treatment of alpha1-antitrypsin deficiencyCENTESSA PHARMACEUTICALS UK LTD·Filed 2022·Granted Jul 22, 2025·0 cites·13 claims
- 1859US12421310B2CD47 binding agentsCENTESSA PHARMACEUTICALS UK LTD·Filed 2019·Granted Sep 23, 2025·0 cites·28 claims
- 1952US12503475B2Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonistsCENTESSA PHARMACEUTICALS UK LTD·Filed 2021·Granted Dec 23, 2025·0 cites·20 claims
- 2042US2025277001A1Peptide derivatives and related uses as orexin agonistsCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CENTESSA PHARMACEUTICALS UK LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →